BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10850895)

  • 1. 1999: a time to re-evaluate AIDS vaccine strategies.
    Ruprecht RM; Hofmann-Lehmann R; Rasmussen RA; Vlasak J; Xu W
    J Hum Virol; 2000; 3(2):88-93. PubMed ID: 10850895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Australia reports on AIDS: nef deletions, live vaccines, Chinese travelers.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1996 Mar; 2(3):6-12, 40. PubMed ID: 11363347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV vaccine design: insights from live attenuated SIV vaccines.
    Koff WC; Johnson PR; Watkins DI; Burton DR; Lifson JD; Hasenkrug KJ; McDermott AB; Schultz A; Zamb TJ; Boyle R; Desrosiers RC
    Nat Immunol; 2006 Jan; 7(1):19-23. PubMed ID: 16357854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconsidering an attenuated vaccine for AIDS.
    Beale J
    Lancet; 1996 Feb; 347(8998):344-5. PubMed ID: 8598696
    [No Abstract]   [Full Text] [Related]  

  • 7. Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine.
    Berkhout B; Verhoef K; Marzio G; Klaver B; Vink M; Zhou X; Das AT
    J Neurovirol; 2002 Dec; 8 Suppl 2():134-7. PubMed ID: 12491165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated HIV vaccine: caveats.
    Ruprecht RM; Baba TW; Liska V
    Science; 1996 Mar; 271(5257):1790-2. PubMed ID: 8596941
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunization for long-term protection against AIDS using the macaque model.
    Kumar A; Narayan O
    Virology; 2001 Jun; 285(1):1-5. PubMed ID: 11414799
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of the development of an AIDS vaccine.
    Lasky LA
    Crit Rev Immunol; 1989; 9(3):153-72. PubMed ID: 2673294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV/AIDS in China. Vaccine development with a distinctly Chinese flavor.
    Cohen J
    Science; 2004 Jun; 304(5676):1437. PubMed ID: 15178780
    [No Abstract]   [Full Text] [Related]  

  • 12. Developments in preclinical AIDS vaccine efficacy models.
    Bogers WM; Cheng-Mayer C; Montelaro RC
    AIDS; 2000; 14 Suppl 3():S141-51. PubMed ID: 11086857
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV/AIDS: vaccines and alternate strategies for treatment and prevention.
    Voronin Y; Phogat S
    Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
    Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
    J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aids vaccine advance.
    Novak K; MacFarlane J; Aamodt S
    Nat Med; 2000 Nov; 6(11):1220. PubMed ID: 11062531
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
    Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
    Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine.
    Desrosiers RC
    AIDS Res Hum Retroviruses; 1994 Apr; 10(4):331-2. PubMed ID: 8068412
    [No Abstract]   [Full Text] [Related]  

  • 18. [Development of an AIDS vaccine: status report].
    Girard MP
    Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the SIV model in AIDS vaccine research.
    Friedrich TC; Watkins DI
    IAVI Rep; 2005; 9(2):1, 6-8. PubMed ID: 16156073
    [No Abstract]   [Full Text] [Related]  

  • 20. AIDS vaccines show promise in primates.
    Clin Infect Dis; 2001 Oct; 33(7):i-ii. PubMed ID: 11592258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.